Scancell in-licences SNAPvax technology for its Modi-2 cancer treatment

(Alliance News) - Scancell Holdings PLC on Monday said it has in-licensed SNAPvax technology from ...

Alliance News 7 November, 2022 | 12:56PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Scancell Holdings PLC on Monday said it has in-licensed SNAPvax technology from Vaccitech PLC to help develop its cancer treatments.

The agreement will allow the Nottingham-based cancer immunotherapies developer to formulate and manufacture Modi-2 with the aim of initiating a Phase 1 clinical study in cancer patients in 2024.

Modi-2 is the second product from Scancell's Moditope platform, which leverages the immune system to target a unique class of post-translational modifications upregulated by many cancers. Upregulation is the process by which a cell increases its response to a substance or signal from outside the cell to carry out a specific function.

Scancell expects that the combination of its Modi-2 with a "highly effective platform" for inducing T cells - Vaccitech's SNAPvax technology - will lead to a "potentially superior" therapeutic vaccine candidate.

Chief Executive Officer Lindy Durrant said: "We are pleased to partner with Vaccitech to take the second candidate from our Moditope platform through good manufacturing practice and subsequent clinical development. With its elegant and effective solution, the SNAPvax technology provides an excellent method for formulation of the Modi-2 vaccine. Combining this technology with our expertise will allow us to develop a rapid manufacturing process for Modi-2, with the hope that we can bring it into a Phase 1 clinical study during 2024."

Shares in Scancell Holdings were trading 4.4% higher at 19.98 pence each in London on Monday around midday.

By Chris Dorrell; chrisdorrell@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Scancell Holdings PLC 9.73 GBX -1.52 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures